These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29575770)

  • 1. Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.
    Korth-Bradley J; Rupon J; Plotka A; Charnigo R; Rendo P
    Clin Transl Sci; 2018 May; 11(3):283-288. PubMed ID: 29575770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of relative bioavailability of two presentations of moroctocog alfa (AF-CC) in subjects with moderately severe or severe hemophilia A.
    Shafer F; Charnigo RJ; Plotka A; Baumann J; Liang Y; Korth-Bradley J
    Clin Pharmacol Drug Dev; 2015; 4(3):237-41. PubMed ID: 27140804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
    Liu H; Wu R; Hu P; Sun F; Xu L; Liang Y; Nepal S; Qu PR; Huard F; Korth-Bradley JM
    Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
    Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
    Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.
    Klamroth R; Simpson M; von Depka-Prondzinski M; Gill JC; Morfini M; Powell JS; Santagostino E; Davis J; Huth-Kühne A; Leissinger C; Neumeister P; Bensen-Kennedy D; Feussner A; Limsakun T; Zhou M; Veldman A; St Ledger K; Blackman N; Pabinger I
    Haemophilia; 2016 Sep; 22(5):730-8. PubMed ID: 27434619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
    Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
    Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
    Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.
    Kessler CM; Gill JC; White GC; Shapiro A; Arkin S; Roth DA; Meng X; Lusher JM
    Haemophilia; 2005 Mar; 11(2):84-91. PubMed ID: 15810908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies.
    Yang R; Zhao Y; Wang X; Sun J; Wu R; Jin C; Jin J; Wu D; Rendo P; Sun F; Rupon J; Huard F; Korth-Bradley JM; Xu L; Luo B; Liu YC
    J Blood Med; 2020; 11():439-448. PubMed ID: 33269010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.
    Klamroth R; Windyga J; Radulescu V; Collins PW; Stasyshyn O; Ibrahim HM; Engl W; Tangada SD; Savage W; Ewenstein B
    Blood; 2021 Apr; 137(13):1818-1827. PubMed ID: 33150384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.
    Abrantes JA; Nielsen EI; Korth-Bradley J; Harnisch L; Jönsson S
    Clin Pharmacol Ther; 2017 Dec; 102(6):977-988. PubMed ID: 28437834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
    Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
    Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
    Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
    Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII recovery after a single infusion of recalibrated ReFacto in 14 severe haemophilia A patients.
    Lambert T; Guérois C; Gay V; Stieltjes N; Bertrand MA; Derlon A; Sigaud M; Hassoun A; Négrier C; Coatmelec B; Dreyfus M; Dubanchet A
    Haemophilia; 2007 Jul; 13(4):357-60. PubMed ID: 17610548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India.
    Choraria N; Rangarajan S; John MJ; Apte S; Gupta P; Pai S; Chand R; Parvatini S; Ramakanth GSH; Rupon J; Chhabra A; Muley HB; Simoneau D
    Indian J Hematol Blood Transfus; 2022 Nov; 39(4):1-6. PubMed ID: 36467512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.